Hospital-acquired vancomycin-resistant enterococci: A report of 2-year experience

Acta Medica Iranica

Volumn 47, Issue 6, 2009, Pages 469-472

  Hasibi, Mehradad ^a   Rezaii, Jalal ^a   Iravani, Babak Mohajer ^a   Moslemi, Seyed Bahram ^a   Haji Abadi, Maziyar Rahimi ^a   Taghavi, Seyed Morteza ^a   Haji Nouri, Mitra ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Enterococci; Gastrointestinal; Risk factors; Vancomycin

Indexed keywords

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; CHRONIC KIDNEY FAILURE; ENTEROCOCCAL INFECTION; FECES ANALYSIS; FECES CULTURE; FEMALE; HEMODIALYSIS; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PREVALENCE; VANCOMYCIN RESISTANT ENTEROCOCCUS; VIRUS ISOLATION;

EID: 75749112154     PISSN: 00446025     EISSN: 00446025     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Centers for Disease Control and Prevention (CDC). Summary of notifiable diseases, United States, 1997. MMWR Morb Mortal Wkly Rep 1998;46(54):ii-vii, 3-87.
2. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000;342(10):710-21.
3. Hayden MK. Insights into the epidemiology and control of infection with vancomycin-resistant enterococci. Clin Infect Dis 2000;31(4):1058-65.
4. Tornieporth NG, Roberts RB, John J, Hafner A, Riley LW. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis 1996;23(4):767-72.
5. Morris JG Jr, Shay DK, Hebden JN, McCarter RJ Jr, Perdue BE, Jarvis W, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med 1995;123(4):250-9.
6. Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev Infect Dis 1987;9(6):1065-78.
7. National Committee for Clinical Laboratory Standards (NCCLS). Performance Standards for Antimicrobial Susceptibility Testing: Thirteenth International Supplement M100-S13, Table 2D. USA: NCCLS, Wayne, PA, 2003.
8. Uttley AH, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1988;1(8575-6):57-8.
9. Martone WJ. Spread of vancomycin-resistant enterococci: why did it happen in the United States? Infect Control Hosp Epidemiol 1998;19(8):539-45.
10. Burrell LJ, Grabsch EA, Padiglione AA, Grayson ML. Prevalence of colonisation with vancomycin-resistant enterococci (VRE) among haemodialysis outpatients in Victoria: implications for screening. Med J Aust 2005;182(9): 492.
11. Streit JM, Jones RN, Sader HS, Fritsche TR. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int J Antimicrob Agents 2004;24(2):111-8.
12. Bonten MJ, Slaughter S, Ambergen AW, Hayden MK, van Voorhis J, Nathan C, et al. Arch Intern Med 1998; 158(10):1127-32.
13. Patel R, Allen SL, Manahan JM, Wright AJ, Krom RA, Wiesner RH, et al. Natural history of vancomycin-resistant enterococcal colonization in liver and kidney transplant recipients. Liver Transpl 2001;7(1):27-31.
14. Perencevich EN, Fisman DN, Lipsitch M, Harris AD, Morris JG Jr, Smith DL. Projected benefits of active surveillance for vancomycin-resistant enterococci in intensive care units. Clin Infect Dis 2004;38(8):1108-15.
15. Puzniak LA, Gillespie KN, Leet T, Kollef M, Mundy LM. A cost-benefit analysis of gown use in controlling vancomycin-resistant Enterococcus transmission: is it worth the price? Infect Control Hosp Epidemiol 2004;25(5):418-24.
16. Chavers LS, Moser SA, Benjamin WH, Banks SE, Steinhauer JR, Smith AM, et al. Vancomycin-resistant enterococci: 15 years and counting. J Hosp Infect 2003;53(3):159-71.
17. Orloff SL, Busch AM, Olyaei AJ, Corless CL, Benner KG, Flora KD, et al. Vancomycin-resistant Enterococcus in liver transplant patients. Am J Surg 1999;177(5):418-22.
18. Zaas AK, Song X, Tucker P, Perl TM. Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci. Clin Infect Dis 2002;35(10):1139-46.
19. Kapur D, Dorsky D, Feingold JM, Bona RD, Edwards RL, Aslanzadeh J, et al. Incidence and outcome of vancomycin-resistant enterococcal bacteremia following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2000;25(2):147-52.
20. Patel R. Clinical impact of vancomycin-resistant enterococci. J Antimicrob Chemother 2003;51 (Suppl 3):iii13-21.